MX359988B - Derivado de pirazol y uso del mismo para propósitos médicos. - Google Patents

Derivado de pirazol y uso del mismo para propósitos médicos.

Info

Publication number
MX359988B
MX359988B MX2014013696A MX2014013696A MX359988B MX 359988 B MX359988 B MX 359988B MX 2014013696 A MX2014013696 A MX 2014013696A MX 2014013696 A MX2014013696 A MX 2014013696A MX 359988 B MX359988 B MX 359988B
Authority
MX
Mexico
Prior art keywords
pyrazole derivative
medical purposes
present
constipation
prevention
Prior art date
Application number
MX2014013696A
Other languages
English (en)
Other versions
MX2014013696A (es
Inventor
Isaji Masayuki
Takemura Masaaki
Isawa Hidetoshi
Hotei Yukihiko
Miyashita Itaru
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MX2014013696A publication Critical patent/MX2014013696A/es
Publication of MX359988B publication Critical patent/MX359988B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona derivados de pirazol, usos de los mismos para los propósitos médicos y similares. Más particularmente, la presente invención se refiere a productos farmacéuticos útiles para la prevención o el tratamiento del estreñimiento, que comprenden como un ingrediente activo 3-(3-{4-[3-(ß-D-glucopiranosiloxi)-5-isopropil-1H-pirazol-4-ilmet il]-3-metilfenoxi}propilamino)-2,2-dimetiIpropionamida, o una sal farmacéuticamente aceptable del mismo. Los productos farmacéuticos de la presente invención ejercen un efecto de aumentar la frecuencia o la defecación o similares, y son útiles para la prevención o el tratamiento del estreñimiento.
MX2014013696A 2012-05-07 2013-05-02 Derivado de pirazol y uso del mismo para propósitos médicos. MX359988B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2014013696A MX2014013696A (es) 2015-02-05
MX359988B true MX359988B (es) 2018-10-18

Family

ID=49550709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013696A MX359988B (es) 2012-05-07 2013-05-02 Derivado de pirazol y uso del mismo para propósitos médicos.

Country Status (16)

Country Link
US (2) US9273085B2 (es)
EP (1) EP2848254B1 (es)
JP (2) JP5663699B2 (es)
KR (1) KR101868991B1 (es)
CN (1) CN104284665B (es)
AU (1) AU2013258566B2 (es)
BR (1) BR112014027841B1 (es)
CA (1) CA2872002C (es)
DK (1) DK2848254T3 (es)
ES (1) ES2601127T3 (es)
HK (1) HK1204773A1 (es)
MX (1) MX359988B (es)
PL (1) PL2848254T3 (es)
PT (1) PT2848254T (es)
RU (1) RU2602739C2 (es)
WO (1) WO2013168671A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
ES2601127T3 (es) * 2012-05-07 2017-02-14 Kissei Pharmaceutical Co., Ltd. Derivado de pirazol y su uso con fines médicos
US10022389B2 (en) 2013-02-04 2018-07-17 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
CA2952405A1 (en) * 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for stabilizing the same
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
MX2020009349A (es) 2018-03-28 2021-04-28 Avolynt Método para el tratamiento de la hipoglucemia posprandial.
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
RU2482122C2 (ru) * 2007-12-27 2013-05-20 Киссеи Фармасьютикал Ко., Лтд. Моносебацинат производного пиразола
CA2725230C (en) 2008-04-16 2016-05-17 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
ES2601127T3 (es) * 2012-05-07 2017-02-14 Kissei Pharmaceutical Co., Ltd. Derivado de pirazol y su uso con fines médicos

Also Published As

Publication number Publication date
US9273085B2 (en) 2016-03-01
EP2848254B1 (en) 2016-08-03
CA2872002C (en) 2019-01-15
DK2848254T3 (en) 2016-10-31
HK1204773A1 (en) 2015-12-04
US20150141631A1 (en) 2015-05-21
RU2602739C2 (ru) 2016-11-20
CA2872002A1 (en) 2013-11-14
JPWO2013168671A1 (ja) 2016-01-07
EP2848254A4 (en) 2015-07-15
WO2013168671A1 (ja) 2013-11-14
CN104284665B (zh) 2016-11-16
PL2848254T3 (pl) 2017-03-31
BR112014027841A2 (pt) 2017-06-27
AU2013258566A1 (en) 2014-11-27
BR112014027841B1 (pt) 2022-08-09
BR112014027841A8 (pt) 2021-09-28
PT2848254T (pt) 2016-10-05
RU2014149181A (ru) 2016-06-27
JP5663699B2 (ja) 2015-02-04
ES2601127T3 (es) 2017-02-14
US20160129031A1 (en) 2016-05-12
KR20150013671A (ko) 2015-02-05
MX2014013696A (es) 2015-02-05
JP2015083580A (ja) 2015-04-30
EP2848254A1 (en) 2015-03-18
KR101868991B1 (ko) 2018-06-19
US9694027B2 (en) 2017-07-04
CN104284665A (zh) 2015-01-14
AU2013258566B2 (en) 2017-03-16
JP6105546B2 (ja) 2017-03-29

Similar Documents

Publication Publication Date Title
MX2014013696A (es) Derivado de pirazol y uso del mismo para propositos medicos.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
NZ628408A (en) Ingenol derivatives in reactivation of latent hiv virus
TN2012000092A1 (en) Therapeutic agent for mood disorders
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
UA107702C2 (en) Novel benzamide derivatives
MX2013002649A (es) Agente terapeutico contra el dolor.
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний

Legal Events

Date Code Title Description
FG Grant or registration